Methicillin Resistant Staphylococcus Aureus (MRSA) infections in the hospital population have shown a dramatic increase. This pilot study determined whether random/fasting blood glucose measurements were performed on patients admitted to hospital with MRSA bacteraemia. We also examined mortality in relationship to hyperglycaemia, defined as random glucose ≥ 11 mmol/L. Retrospective data for all in-patients aged ≥ 16 years for the three years; 2000—2002 identified 309 patients with MRSA bacteraemia and all of them had laboratory blood glucose concentrations recorded on admission in all cases. A random blood glucose ≥ 11 mmol/L was noted in 129 (42%) patients of whom 82 (64%) died. The mortality was significantly more likely to be in the highest tertile (p<0.05) of blood glucose distributions.
The first year of the Department of Health's mandatory MRSA bacteraemia surveillance scheme in acute NHS trusts in England: April 2001-March 2002. CDR Weekly2002;12:1-17.
Duckworth G.Controlling methicillin resistant Staphylococcus aureus: time to return to more stringent methods of control in the United Kingdom?BMJ2003;327:1177-8.
5.
Griffiths C. , Lamagni TL, Crowcroft NS, Duckworth G., Rooney C.Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993-2002 . Health Stat Q2004;(21):15-22.
6.
Commission for Health Improvement.Methicillin resistant Staphylococcus aureus (MRSA) improvement score . London: CHI, 2003. http://www.chi.nhs.uk/Ratings/Trust/Indicator
7.
Crowcroft NS , Catchpole M.Mortality from methicillin resistant Staphylococcus aureus in England and Wales: analysis of death certificates . BMJ2002;325:1390-1.
8.
Tentolouris N. , Jude EB, Smirnof I., Knowles EA, Boulton AJMethicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med1999;16:767-71.
9.
Turner JM, Hakeem LM, Lockman KA, Bhattacharyya DN, Campbell IWDiabetic MRSA foot infection - role of linezolid therapy. Br J Diabetes Vasc Dis2004;4:44-6.
10.
Coast J., Smith R., Karcher AM, Wilton P., Millar M.Superbugs II: how should economic evaluation be conducted for interventions, which aim to contain antimicrobial resistance?Health Econ2002;11:637-47.
11.
Philips BJ, Redman J., Brennan A. et al. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubate patients. Thorax2005;60:761-4.
12.
Pratt RJ, Pellow C., Loveday HP, Robinson N., Smith GW, and the EPIC guideline development team.The EPIC project: developing national evidence-based guidelines for preventing healthcare associated infections. J Hosp Infect2001;47(suppl):3-4S.